Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation.

In this study, although the differences in median PFS (26.9 vs 18.3 months) and OS (33.7 vs 30.7 months) between the ≥65 and <65 age groups did not reach statistical significance, observable numerical differences were noted.

also in 111,027 other papers